

Technology Advisory Committee D Interests Register

Topic: Pembrolizumab for previously treated solid tumours with high microsatellite instability or mismatch repair deficiency [ID4036]

Publication Date: 20/09/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor David Meads	Committee Member	Non-Financial Professional Interests	University of Leeds has received funding from BMS for research in an unrelated area.	30.06.2023	It was agreed his declaration would not prevent Professor Meads from attending discussions for this appraisal.
Dr Matthew Bradley	Committee Member	Financial	Dr Bradley is an employee of GSK who are a named competitor manufacturer of pembrolizumab in this indication.	22.06.2023	It was agreed as a direct financial conflict Dr Bradley would not attend discussions for this appraisal.
Dr Kai-Keen Shiu	Clinical Expert	Direct and Indirect Financial	Direct institutional funding to UCLH NHS Foundation Trust and/or University College London for running MSD clinical trials as Chief Investigator or Principal Investigator.	15.11.2022	It was agreed his declarations would not prevent Dr Shiu from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Educational meetings or advisory boards for MSD for which I was given honoraria.</p> <p>BMS - personal honoraria for attendance of advisory boards, chairing educational meeting and invited lectures.</p> <p>Servier - Direct (personal) honoraria or funding or attendance at advisory boards; chairing educational meetings; giving invited lectures; travel, accommodation and registration at national/international meetings.</p>		